BioWorld

Dec. 17, 2004

View Archived Issues

Sepracor Gets FDA Approval For Insomnia Drug, Lunesta

Read More

Serologicals Raises $127M, Adds To 2004's Money Total

Read More

Other News To Note

Read More

Amgen's Kepivance Approved For Mucositis In Blood Cancers

As expected, Amgen Inc. won FDA approval of Kepivance (palifermin), its fast-track keratinocyte growth factor for mucositis in chemotherapy patients with blood cancers who get bone marrow transplants. (BioWorld Today) Read More

CancerVax Partners Canvaxin With Serono For Up To $290M

Read More